Samsung Bioepis to develop biosimilars for Merck
Samsung Bioepis Co. Ltd., a joint venture between Samsung BioLogics and Biogen Idec Inc., has agreed to develop biosimilars for Merck & Co. Inc. Specific targets and candidates were not disclosed, but the companies state that multiple projects are involved.
- Large Molecule
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.